Prescription Drug
Misuse, Abuse and Dependence
|
Project Title |
Prescription Drug
Misuse, Abuse and Dependence |
|
Funding Source |
NIDA |
|
Project Dates |
11/2006-06/2010
|
|
Project Number |
5
R01DA020791 |
|
Team |
Principal
Investigator-
Linda B. Cottler, PhD, MPH
Co-Investigators-
Theodore Cicero, PhD
Lee Hoffer,
PhD
Michael Lynskey, PhD
Clinician-
Catherine Striley, PhD, LCSW
Project
Coordinator-
Tamara Millay
Research
Statistician-
Arbi Ben Abdallah, MS
|
Abstract
This R01 responds to NIDA RFA PA-04-110:
Prescription Drug Abuse. According to the 2005 National Survey on Drug
Use and Health, past month non-medicinal use of prescription-type drugs
among young adults is 6.3%. This is a dramatic increase from the 5.4%
that was reported in the 2002 survey. This rise in use is a public health
concern that impacts people of all ages, but particularly those between
the ages of 18-25 and 50-65. This trend is among the nations most
important problems due to its physical, social, and psychiatric
consequences. Yet, publications to date have largely focused solely on
prevalence rather than assess associated problems. Without this
information, there is no viable way to create a useful public health
response.
With these facts in
mind, the research team intends to interview 400 current and past year
drug users--50% aged 18-25 and 50% aged 50-65. The nosological aims of
this study include:
1) Conduct
qualitative research on prescription drug users and health professionals
to understand contextual factors related to prescription drug (stimulants,
sedatives and opioids) misuse and its consequences. The data will inform
revisions to the Substance Abuse Module (SAM) and Risk Behavior Assessment
(RBA) for the quantitative study. Focus group topics for user groups and
health professional groups will include those salient to the field. We
will also conduct an ethnographic sub-study to explain the findings of the
quantitative study.
2) Evaluate
the inter-rater reliability and validity of the SAM questions, criteria,
and abuse of and dependence on each category of prescription drugs.
Compare the reliability and validity of these drugs to that for other
illicit drugs assessed in the SAM.
3) Understand
reasons for poor reliability and misunderstood questions through the use
of our computerized Discrepancy Interview Protocol (DIP) and Debriefing
Interview, to “perfect” assessments.
4) Evaluate
nosological issues about prescription drug abuse and dependence.
5) Share
findings with the Missouri Statewide Epidemiology Work Group, the NIDA
Community Epidemiology Work Group, and the DSM-V and ICD XI Substance
Related Disorders Committees.
Epidemiology and Prevention Research Group 
